Good evening :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Jagsonpal Pharmaceuticals Ltd

JAGSNPHARM

Jagsonpal Pharmaceuticals Ltd

JAGSNPHARM
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,690 cr, stock is ranked 1,201
High RiskStock is 3.76x as volatile as Nifty
637.707.61% (+45.10)
637.707.61% (+45.10)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,690 cr, stock is ranked 1,201
High RiskStock is 3.76x as volatile as Nifty
Scorecard

Performance

High

The creamy layer - amongst the top performing stocks

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,690 cr, stock is ranked 1,201
High RiskStock is 3.76x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
69.589.020.78%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
50.266.380.53%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Jagsonpal Pharmaceuticals Limited is engaged in pharmaceutical business. It specializes in developing and manufacturing bulk drugs and pharmaceutical formulations.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 5.31%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.08% to 0.06%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 25.48%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue144.15157.14126.99168.26161.10192.34221.01242.44217.98234.96
Raw Materialssubtract65.3567.3465.1953.4354.9475.5083.3588.0476.08197.56
Power & Fuel Costsubtract2.262.121.001.410.640.520.470.290.17
Employee Costsubtract37.8440.9541.8846.6150.3753.9857.6865.1861.80
Selling & Administrative Expensessubtract26.5830.1927.5632.2338.3431.8842.5041.6641.09
Operating & Other expensessubtract-0.34-2.502.0123.815.756.998.5610.856.50
Depreciation/Amortizationsubtract3.091.990.321.021.131.091.531.211.664.22
Interest & Other Itemssubtract5.302.640.660.750.510.510.290.410.810.90
Taxes & Other Itemssubtract0.832.53-0.081.781.544.827.788.097.417.98
EPS1.244.53-4.412.763.016.517.2010.208.539.19
DPS0.100.100.100.250.501.004.005.005.005.00
Payout ratio0.080.02—0.090.170.150.560.490.590.54
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF

Investor Presentation

Feb 22PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Jagsonpal Pharmaceuticals Ltd75.289.020.78%
Sun Pharmaceutical Industries Ltd44.986.420.75%
Cipla Ltd29.134.480.87%
Torrent Pharmaceuticals Ltd64.7115.630.88%

Price Comparison

Compare JAGSNPHARM with any stock or ETF
Compare JAGSNPHARM with any stock or ETF
JAGSNPHARM
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Increased Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has increased by 1.19%

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding67.97%0.11%0.00%2.30%29.62%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.37%0.38%0.53%0.73%1.10%2.30%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

JAGSNPHARM has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.78%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹7.82 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 6, 2024

Final
Final | Div/Share: ₹5.00

Dividend/Share

₹5.00

Ex DateEx Date

Sep 6, 2024

Cash Dividend

Ex DateEx DateAug 21, 2023

Final
Final | Div/Share: ₹5.00

Dividend/Share

₹5.00

Ex DateEx Date

Aug 21, 2023

Cash Dividend

Ex DateEx DateOct 29, 2021

Interim
Interim | Div/Share: ₹4.00

Dividend/Share

₹4.00

Ex DateEx Date

Oct 29, 2021

Cash Dividend

Ex DateEx DateSep 22, 2021

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 22, 2021

Cash Dividend

Ex DateEx DateSep 22, 2020

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Sep 22, 2020

News & Opinions
Earnings
Jagsonpal Pharmaceuticals standalone net profit rises 53.41% in the September 2024 quarter

Net profit of Jagsonpal Pharmaceuticals rose 53.41% to Rs 11.46 crore in the quarter ended September 2024 as against Rs 7.47 crore during the previous quarter ended September 2023. Sales rose 29.15% to Rs 74.69 crore in the quarter ended September 2024 as against Rs 57.83 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales74.6957.83 29 OPM %21.8114.47 - PBDT17.7110.42 70 PBT15.379.96 54 NP11.467.47 53 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals to table results

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 23 October 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Jagsonpal Pharmaceuticals standalone net profit declines 28.74% in the June 2024 quarter

Net profit of Jagsonpal Pharmaceuticals declined 28.74% to Rs 5.33 crore in the quarter ended June 2024 as against Rs 7.48 crore during the previous quarter ended June 2023. Sales rose 2.14% to Rs 61.44 crore in the quarter ended June 2024 as against Rs 60.15 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales61.4460.15 2 OPM %16.6814.35 - PBDT11.4710.48 9 PBT10.4010.09 3 NP5.337.48 -29 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals declare Quarterly Result

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 August 2024Powered by Capital Market - Live

3 months agoCapital Market - Live